BUZZ — Keymed Biosciences hits near 3 — month high on product revenue growth

* Shares of Keymed Biosciences jump 12.5% to HK$85.7, their highest level since July 24 * Stock of biological therapies developer on course for biggest one-day pct rise since June 29 after three consecutive sessions of falls * Keymed recorded about 660 million yuan ($98.63 million) in revenue from product Kangyueda during the first three quarters of 2026, up 227% y/y on support of national policies * Kangyueda is the trade name of IL-4Rα monoclonal antibody stapokibart for treatment of inflammatory diseases * China's National Medical Products Administration has approved marketing application for new indication of stapokibart for treatment of atopic dermatitis in adolescents * YTD, stock up 58.2%, Hang Seng Biotech Index up 6.47% ($1 = 6.6918 Chinese yuan) (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com)